Journal article

Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss.

Emily A Day, Rebecca J Ford, Brennan K Smith, Pedrum Mohammadi-Shemirani, Marisa R Morrow, Robert M Gutgesell, Rachel Lu, Amogelang R Raphenya, Mostafa Kabiri, Andrew G McArthur, Natalia McInnes, Sibylle Hess, Guillaume Paré, Hertzel C Gerstein, Gregory R Steinberg

Nature Metabolism | Published : 2019

Abstract

Metformin is the most commonly prescribed medication for type 2 diabetes, owing to its glucose-lowering effects, which are mediated through the suppression of hepatic glucose production (reviewed in refs. 1-3). However, in addition to its effects on the liver, metformin reduces appetite and in preclinical models exerts beneficial effects on ageing and a number of diverse diseases (for example, cognitive disorders, cancer, cardiovascular disease) through mechanisms that are not fully understood1-3. Given the high concentration of metformin in the liver and its many beneficial effects beyond glycemic control, we reasoned that metformin may increase the secretion of a hepatocyte-derived endocri..

View full abstract